UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Cancer cell, 2019-02, Vol.35 (2), p.238-255.e6

2019

Volltextzugriff (PDF)

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Nature medicine, 2019-06, Vol.25 (6), p.929-935

2019

Volltextzugriff (PDF)

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Cancer cell, 2016-04, Vol.29 (4), p.477-493

2016

Volltextzugriff (PDF)

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Nature communications, 2021-02, Vol.12 (1), p.1137-1137, Article 1137

2021

Volltextzugriff (PDF)

Robust network inference using response logic

Bioinformatics, 2019-07, Vol.35 (14), p.i634-i642

2019

Volltextzugriff (PDF)

Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure

Cancer cell, 2017-08, Vol.32 (2), p.221-237.e13

2017

Volltextzugriff (PDF)

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Breast cancer research and treatment, 2022-02, Vol.191 (3), p.565-576

2022

Volltextzugriff (PDF)

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Nature communications, 2023-09, Vol.14 (1), p.5945-5945, Article 5945

2023

Volltextzugriff (PDF)

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Clinical cancer research, 2022-03, Vol.28 (5), p.993-1003

2022

Volltextzugriff (PDF)

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Clinical cancer research, 2024-10, Vol.30 (19), p.4329-4338

2024

Volltextzugriff (PDF)

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Investigational new drugs, 2020-04, Vol.38 (2), p.419-432

2020

Volltextzugriff (PDF)

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

NPJ precision oncology, 2018-03, Vol.2 (1), p.7-7, Article 7

2018

Volltextzugriff (PDF)

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes

Nature communications, 2022-05, Vol.13 (1), p.2841-2841, Article 2841

2022

Volltextzugriff (PDF)

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

The lancet oncology, 2017-11, Vol.18 (11), p.e638-e638

2017

Volltextzugriff (PDF)

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Clinical cancer research, 2021-02, Vol.27 (4), p.1162-1173

2021

Volltextzugriff (PDF)

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Investigational new drugs, 2021-02, Vol.39 (1), p.163-174

2021

Volltextzugriff (PDF)

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

Cell death and differentiation, 2019-11, Vol.26 (11), p.2416-2429

2019

Volltextzugriff (PDF)

Next-Generation Estrogen Receptor-Targeted Therapeutics

Annual review of cancer biology, 2023-04, Vol.7 (1), p.313-330

2023

Volltextzugriff (PDF)

Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Clinical cancer research, 2017-09, Vol.23 (17), p.5238-5245

2017

Volltextzugriff (PDF)

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

Cancer chemotherapy and pharmacology, 2013-05, Vol.71 (5), p.1315-1323

2013

Volltextzugriff (PDF)

Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer

JCO precision oncology, 2020-11 (4), p.1012-1024

2020

Volltextzugriff (PDF)

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Clinical cancer research, 2019-06, Vol.25 (11), p.3239-3246

2019

Volltextzugriff (PDF)

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Pigment cell and melanoma research, 2018-07, Vol.31 (4), p.516-522

2018

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(79)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(80)

Sprache

Englisch
(80)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Humans
(25)
Oncology
(25)
Female
(15)
Tumors
(12)
Melanoma
(11)
Metastases
(11)
Mutation
(11)
Male
(10)
Melanoma - Genetics
(10)
Middle Aged
(10)
Treatment Outcome
(10)
Aged
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Breast Cancer
(8)
Cell Biology
(8)
Melanoma - Drug Therapy
(8)
Metastasis
(8)
Proto-Oncogene Proteins B-Raf - Genetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2

Tumour gene expression signature in primary melanoma predicts long-term outcomes

Robust network inference using response logic

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Tumor-intrinsic expression of the autophagy gene Atg16l1 suppresses anti-tumor immunity in colorectal cancer

Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

Author Correction: Tumour gene expression signature in primary melanoma predicts long-term outcomes

Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

Next-Generation Estrogen Receptor-Targeted Therapeutics

Gene Expression Profiling in BRAF -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600 -mutated Metastatic Melanoma

Association of programmed death ligand‐1 (PD‐L1) expression with treatment outcomes in patients with BRAF mutation‐positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib

Suchergebnisse filtern